AR081049A1 - OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA - Google Patents
OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIAInfo
- Publication number
- AR081049A1 AR081049A1 ARP100103007A AR081049A1 AR 081049 A1 AR081049 A1 AR 081049A1 AR P100103007 A ARP100103007 A AR P100103007A AR 081049 A1 AR081049 A1 AR 081049A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- farsightedness
- ophthalmic
- includes association
- ophthalmic medicament
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion1: Medicamentos oftálmicos para el tratamiento de la hipermetropía incluyendo agente de accion anti-colinérgica en su formulacion. Reivindicacion 2: Medicamento oftálmico para el tratamiento de la hipermetropía incluyendo clorhidrato de pilocarpina en concentracion es de entre 0,05% a 2% en su formulacion. Reivindicacion 3: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con otro fármaco de accion adrenérgica. Reivindicacion 4: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con tetrahidrozolina entre 5 y 50 mg%. Reivindicacion 5: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con fenilefrina entre 5 y 50 mg%. Reivindicacion 6: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con nafazolina entre 1.2 y 12 mg%. Reivindicacion 7: Medicamento oftálmico para el tratamiento de la hipermetropía como reivindicada en la reivindicacion 2 a la que se incluye asociacion con oximetazolina entre 1,2 y 12 mg%.Claim 1: Ophthalmic drugs for the treatment of farsightedness including anti-cholinergic action agent in its formulation. Claim 2: Ophthalmic medicament for the treatment of farsightedness including pilocarpine hydrochloride in concentration is between 0.05% to 2% in its formulation. Claim 3: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with another adrenergic action drug. Claim 4: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with tetrahydrozoline between 5 and 50 mg%. Claim 5: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with phenylephrine between 5 and 50 mg%. Claim 6: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with nafazolin between 1.2 and 12 mg%. Claim 7: Ophthalmic medicament for the treatment of farsightedness as claimed in claim 2 which includes association with oxymetazoline between 1.2 and 12 mg%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP100103007 AR081049A1 (en) | 2010-08-17 | 2010-08-17 | OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP100103007 AR081049A1 (en) | 2010-08-17 | 2010-08-17 | OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081049A1 true AR081049A1 (en) | 2012-06-06 |
Family
ID=46379347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103007 AR081049A1 (en) | 2010-08-17 | 2010-08-17 | OPHTHALMIC DRUG FOR THE TREATMENT OF HYPERMETROPIA |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR081049A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9579308B2 (en) | 2011-09-20 | 2017-02-28 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
US10610518B2 (en) | 2018-04-24 | 2020-04-07 | Allergan, Inc. | Presbyopia treatments |
-
2010
- 2010-08-17 AR ARP100103007 patent/AR081049A1/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9579308B2 (en) | 2011-09-20 | 2017-02-28 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
US10610518B2 (en) | 2018-04-24 | 2020-04-07 | Allergan, Inc. | Presbyopia treatments |
US11285134B2 (en) | 2018-04-24 | 2022-03-29 | Allergan, Inc. | Presbyopia treatments |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121843A2 (en) | OPHTHALMIC FORMULATION AND METHOD TO IMPROVE PRESBYOPIA | |
CL2015002680A1 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and method of using them. | |
CR11724A (en) | AGENT TO TREAT DISEASES | |
CR11723A (en) | AGENT TO TREAT DISEASE | |
DOP2012000299A (en) | 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE | |
CL2013001982A1 (en) | Method to reduce glucose levels and treat metabolic disorders; pharmaceutical composition comprising metformin and another antidiabetic or antiobesity agent. | |
EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
BR112012006283A2 (en) | stabilized adamts13 formulation, method for manufacturing a stabilized adamts13 formulation, kit, and methods for treating or preventing a disease and for treating or preventing a stroke | |
DOP2006000057A (en) | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT | |
AR094269A1 (en) | ADDRESS DRUG TO GPC3 TO ADMINISTER A PATIENT RESPONDING TO THERAPY WITH ADDRESS DRUGS TO GPC3 | |
BR112015005940A2 (en) | process for the preparation of therapeutic nanoparticles | |
MX346312B (en) | Ophthalmic treatments. | |
EA201001577A1 (en) | DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION | |
MX2012000275A (en) | Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement. | |
CL2010001406A1 (en) | Ophthalmic pharmaceutical composition comprising povidone iodine, and a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial, an anti-allergic or an anti-glaucoma compound; and method to preserve the composition. | |
AR060019A1 (en) | PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER | |
PE20140255A1 (en) | DISPERSIBLE TABLET IN ORAL FORM | |
AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
UY30158A1 (en) | USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT | |
NI201400003A (en) | A NEW THERAPEUTIC COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT | |
CO7151496A2 (en) | Therapeutic agents for optimized subcutaneous administration | |
CO7101244A2 (en) | Substituted phenylimidazopyrazoles and their use | |
BR112013027010A2 (en) | method of producing substances with supersaturated gas, device for their transdermal delivery, and their uses | |
MD4538B1 (en) | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia | |
BR112014007177A2 (en) | antifungal agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |